Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study

Journal of Clinical Psychiatry

Volumn 69, Issue 1, 2008, Pages 106-113

  Perkins, Diana O ^a   Gu, Hongbin ^a   Weiden, Peter J ^b   McEvoy, Joseph P ^c   Hamer, Robert M ^a   Lieberman, Jeffrey A ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AKATHISIA; AKINESIA; ARTICLE; CANADA; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERSALIVATION; INCONTINENCE; INDEPENDENT VARIABLE; INSOMNIA; LIBIDO; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; NOCTURIA; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY ANALYSIS; SEXUAL AROUSAL DISORDER; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE; SURVIVAL; TREATMENT FAILURE; TREATMENT RESPONSE; UNITED STATES; URINARY HESITANCY; WEIGHT GAIN; XEROSTOMIA;

EID: 39549098323     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0114     Document Type: Article

References (43)

1. Perkins DO, Johnson JL, Hamer RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006;83:53-63
2. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286-290
3. Mojtabai R, Lavelle J, Gibson PJ, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv 2002;53:337-339
4. Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439-446
5. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002;57:209-219
6. Verdoux H, Lengronne J, Liraud F, et al. Medication adherence in psychosis: predictors and impact on outcome: a 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2000;102:203-210
7. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-1842
8. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897
9. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247
10. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(suppl 2):1-56
11. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
12. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128
13. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108
14. Garcia-Cabeza I, Gomez JC, Sacristan JA, et al. Subjective response to antipsychotic treatment and compliance in schizophrenia: a naturalistic study comparing olanzapine, risperidone, and haloperidol (EFESO Study). BMC Psychiatry 2001;1:7
15. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;17:65-68
16. Opolka JL, Rascati KL, Brown CM, et al. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003;37:625-630
17. Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004;65:354-360
18. Menzin, J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003;54:719-723
19. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30:255-264
20. Dossenbach M, Arango-Davila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005;66:1021-1030
21. Joyce AT, Harrison DJ, Loebel AD, et al. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care 2005;11(suppl 8):S254-S261
22. Lieberman J, McEvoy JP, Perkins D, et al. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. Eur Neuropsychopharmacol 2005;15(suppl 3):S525
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994
24. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
26. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV (SCID). Washington, DC: American Psychiatric Press; 1997
27. McEvoy JP, Apperson LJ, Appelbaum PS, et al. Insight in schizophrenia: its relationship to acute psychopathology. J Nerv Ment Dis 1989;177:43-47
28. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251
29. Drake RE, Mueser KT, McHugo GJ. Clinician rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). In: Sederer LI, Dickey B, eds. Outcomes Assessment in Clinical Practice. Belmont, Mass: Williams & Wilkins; 1996: 113-116
30. Malla A, Norman R, McLean T, et al. A Canadian programme for early intervention in non-affective psychotic disorders. Aust N Z J Psychiatry 2003;37:407-413
31. Petersen L, Jeppesen P, Thorup A, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005;331:602
32. Malla AK, Norman RM, Manchanda R, et al. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 2002;32:1109-1119
33. Malla A, Norman R, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a 2-year outcome study. Psychol Med 2006;36:649-658
34. Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 2006;21:29-33
35. Bane C, Hughes CM, McElnay JC. The impact of depressive symptoms and psychosocial factors on medication adherence in cardiovascular disease. Patient Educ Couns 2006;60:187-193
36. Mehta SH, Thomas DL, Sulkowski MS, et al. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 2005;19(suppl 3):S179-S189
37. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-921
38. Sobel RM, Markov D. The impact of anxiety and mood disorders on physical disease: the worried not-so-well. Curr Psychiatry Rep 2005;7:206-212
39. Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19:415-422
40. Hassan M, Madhavan S, Rajagopalan K, et al. Adherence and persistence with antipsychotic therapy among schizophrenia patients in a state Medicaid population [abstract]. J Manag Care Pharm 2006;12:174
41. Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. Biol Psychiatry 2000;47:762-766
42. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005;133:129-133
43. Malla AK, Norman RM, Manchanda R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res 2002;54:231-242